BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10778952)

  • 1. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.
    Folpe AL; Lyles RH; Sprouse JT; Conrad EU; Eary JF
    Clin Cancer Res; 2000 Apr; 6(4):1279-87. PubMed ID: 10778952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
    Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J
    Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
    Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
    Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography.
    Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Hasegawa T
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):683-91. PubMed ID: 16506050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study.
    Stefanou DG; Nonni AV; Agnantis NJ; Athanassiadou SE; Briassoulis E; Pavlidis N
    Anticancer Res; 1998; 18(6B):4673-81. PubMed ID: 9891539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
    Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
    Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma.
    Eary JF; Conrad EU; Bruckner JD; Folpe A; Hunt KJ; Mankoff DA; Howlett AT
    Clin Cancer Res; 1998 May; 4(5):1215-20. PubMed ID: 9607579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.
    Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M
    AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
    Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
    Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
    Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gastric cancer and tumor growth regulation. Study of cell proliferation markers and protein complex p53/p21WAF1/CIP1/mdm-2].
    Villaseca M; Araya JC; Roa I; Roa JC
    Rev Med Chil; 2000 Feb; 128(2):127-36. PubMed ID: 10962880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma.
    Ahlén J; Wejde J; Brosjö O; von Rosen A; Weng WH; Girnita L; Larsson O; Larsson C
    Clin Cancer Res; 2005 Jan; 11(1):206-16. PubMed ID: 15671548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
    Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
    J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
    Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
    Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semi-Quantitative Calculations of Primary Tumor Metabolic Activity Using F-18 FDG PET/CT as a Predictor of Survival in 92 Patients With High-Grade Bone or Soft Tissue Sarcoma.
    Andersen KF; Fuglo HM; Rasmussen SH; Petersen MM; Loft A
    Medicine (Baltimore); 2015 Jul; 94(28):e1142. PubMed ID: 26181552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E
    Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas.
    Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
    Pol J Pathol; 1999; 50(1):9-16. PubMed ID: 10412269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
    Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.